PITTSBURGH, Oct. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that the Third Circuit Court of Appeals denied its motion for an interim injunction pending an on-going appeal of a recent New Jersey District Court decision relating to generic Paroxetine CR. The New Jersey District Court previously denied Mylan's motion for a preliminary injunction, and the appeal of that decision will now continue before the Third Circuit. Mylan is disappointed by the decision, which does not reflect a final decision on the merits of Mylan's claims, and Mylan will continue to pursue its claims.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.
|SOURCE Mylan Inc.|
Copyright©2010 PR Newswire.
All rights reserved